Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial.
Kellokumpu-Lehtinen PL, Marttila T, Jekunen A, Hervonen P, Klintrup K, Kataja V, Utriainen T, Luukkaa M, Leskinen M, Pulkkanen K, Kautio AL, Huttunen T. Kellokumpu-Lehtinen PL, et al. Among authors: marttila t. Anticancer Res. 2020 Dec;40(12):6915-6921. doi: 10.21873/anticanres.14715. Epub 2020 Dec 7. Anticancer Res. 2020. PMID: 33288585 Clinical Trial.
2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial.
Lehtonen M, Sormunen J, Luukkaala T, Marttila T, McDermott R, Joensuu T, Lehtinen I, Ginman C, Kellokumpu-Lehtinen PL. Lehtonen M, et al. Among authors: marttila t. Acta Oncol. 2022 Aug;61(8):963-971. doi: 10.1080/0284186X.2022.2098680. Epub 2022 Jul 18. Acta Oncol. 2022. PMID: 35847998 Clinical Trial.
Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
Marttila T, Järvinen R, Liukkonen T, Rintala E, Boström P, Seppänen M, Tammela T, Hellström P, Aaltomaa S, Leskinen M, Raitanen M, Kaasinen E; FinnBladder Group. Marttila T, et al. Eur Urol. 2016 Aug;70(2):341-7. doi: 10.1016/j.eururo.2016.03.034. Epub 2016 Apr 13. Eur Urol. 2016. PMID: 27085624 Clinical Trial.
Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial.
Kellokumpu-Lehtinen PL, Hjälm-Eriksson M, Thellenberg-Karlsson C, Åström L, Franzen L, Marttila T, Seke M, Taalikka M, Ginman C; SPCG-13. Kellokumpu-Lehtinen PL, et al. Among authors: marttila t. Prostate Cancer Prostatic Dis. 2012 Sep;15(3):303-7. doi: 10.1038/pcan.2012.13. Prostate Cancer Prostatic Dis. 2012. PMID: 22546837 Clinical Trial.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2020 Sep 10;383(11):1040-1049. doi: 10.1056/NEJMoa2001342. N Engl J Med. 2020. PMID: 32905676 Clinical Trial.
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14. N Engl J Med. 2019. PMID: 30763142 Clinical Trial.
59 results